Broadcast Date: 
  • Time: 

The development and manufacturing of biologics is an increasingly complex process that requires a deep understanding of cutting-edge science and innovative technology. In addition, given the relative value of being first to market, biopharmaceutical companies want to shrink the ten or more years it usually takes for a biologic candidate to progress from drug discovery to regulatory approval. Partnering with the right CDMO can help organizations increase production speeds and reduce overall risk while maintaining high-quality products.  

In this GEN webinar, our guest speakers, Dr. Tyler Jones and Senior Research Scientist Dylan Ting will discuss strategies to leverage efficiency from cell line development to clinical manufacturing of biologics. Moreover, we will hear how proprietary technology, creative process engineering using single-use equipment, and meticulous quality control can result in the most efficient route to GMP manufacturing of clinical-phase drug substances.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Produced with support from:

Curia logo
Tyler Jones
Tyler Jones, PhD
Director, Formulation
Dylan Ting
Dylan Ting
Sr. Research Scientist, Process Development